Last reviewed · How we verify
Epaminurad, Naproxen
Epaminurad, Naproxen is a Small molecule drug developed by JW Pharmaceutical. It is currently in Phase 1 development. Also known as: URC102, Naxen.
At a glance
| Generic name | Epaminurad, Naproxen |
|---|---|
| Also known as | URC102, Naxen |
| Sponsor | JW Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epaminurad, Naproxen CI brief — competitive landscape report
- Epaminurad, Naproxen updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI
Frequently asked questions about Epaminurad, Naproxen
What is Epaminurad, Naproxen?
Epaminurad, Naproxen is a Small molecule drug developed by JW Pharmaceutical.
Who makes Epaminurad, Naproxen?
Epaminurad, Naproxen is developed by JW Pharmaceutical (see full JW Pharmaceutical pipeline at /company/jw-pharmaceutical).
Is Epaminurad, Naproxen also known as anything else?
Epaminurad, Naproxen is also known as URC102, Naxen.
What development phase is Epaminurad, Naproxen in?
Epaminurad, Naproxen is in Phase 1.
Related
- Manufacturer: JW Pharmaceutical — full pipeline
- Also known as: URC102, Naxen
- Compare: Epaminurad, Naproxen vs similar drugs
- Pricing: Epaminurad, Naproxen cost, discount & access